Cassia  Cearley net worth and biography

Cassia Cearley Biography and Net Worth

Insider of Icosavax
Cassia Cearley, Ph.D. is the Chief Business Officer (CBO) of Icosavax. Cassia has worked with pharmaceutical companies in various roles for more than 10 years. Prior to joining Icosavax, Cassia was the vice president of research for Aptinyx Inc., where she led a team responsible for building a portfolio of small molecule NMDA receptor modulators. Prior to this, Cassia was on the corporate development team of Naurex Inc, which was responsible for the spinout of Aptinyx Inc. and the sale of Naurex to Allergan. Previously, Cassia worked at Takeda Pharmaceuticals, where she was the director of portfolio management. Prior to Takeda, Cassia was an engagement manager with the life sciences practice of L.E.K. Consulting. Cassia received a Ph.D. in neuroscience from University of Pennsylvania and a B.S. in neuroscience from the Washington State University Honors College.

What is Cassia Cearley's net worth?

The estimated net worth of Cassia Cearley is at least $2.01 million as of December 13th, 2023. Dr. Cearley owns 131,200 shares of Icosavax stock worth more than $2,008,672 as of July 21st. This net worth evaluation does not reflect any other investments that Dr. Cearley may own. Additionally, Dr. Cearley receives an annual salary of $632,150.00 as Insider at Icosavax. Learn More about Cassia Cearley's net worth.

How old is Cassia Cearley?

Dr. Cearley is currently 41 years old. There are 4 older executives and no younger executives at Icosavax. The oldest executive at Icosavax is Mr. Niranjan Kanesa-thasan M.D., Chief Medical Officer, who is 63 years old. Learn More on Cassia Cearley's age.

What is Cassia Cearley's salary?

As the Insider of Icosavax, Inc., Dr. Cearley earns $632,150.00 per year. There are 2 executives that earn more than Dr. Cearley. The highest earning executive at Icosavax is Mr. Adam K. Simpson, President, CEO, Co-Founder & Director, who commands a salary of $855,950.00 per year. Learn More on Cassia Cearley's salary.

How do I contact Cassia Cearley?

The corporate mailing address for Dr. Cearley and other Icosavax executives is , , . Icosavax can also be reached via phone at 206-737-0085 and via email at [email protected]. Learn More on Cassia Cearley's contact information.

Has Cassia Cearley been buying or selling shares of Icosavax?

Cassia Cearley has not been actively trading shares of Icosavax during the last quarter. Most recently, Cassia Cearley sold 8,759 shares of the business's stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $16.01, for a transaction totalling $140,231.59. Following the completion of the sale, the insider now directly owns 131,200 shares of the company's stock, valued at $2,100,512. Learn More on Cassia Cearley's trading history.

Are insiders buying or selling shares of Icosavax?

During the last year, insiders at the sold shares 10 times. They sold a total of 280,376 shares worth more than $4,243,791.73. The most recent insider tranaction occured on February, 1st when CEO Adam K Simpson sold 15,000 shares worth more than $229,350.00. Insiders at Icosavax own 30.6% of the company. Learn More about insider trades at Icosavax.

Information on this page was last updated on 2/1/2024.

Cassia Cearley Insider Trading History at Icosavax

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2023Sell8,759$16.01$140,231.59131,200View SEC Filing Icon  
5/23/2023Sell10,000$10.00$100,000.00141,847View SEC Filing Icon  
3/6/2023Sell5,000$7.75$38,750.00151,847View SEC Filing Icon  
3/7/2022Sell10,000$17.16$171,600.00View SEC Filing Icon  
See Full Table

Cassia Cearley Buying and Selling Activity at Icosavax

This chart shows Cassia Cearley's buying and selling at Icosavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Icosavax Company Overview

Icosavax logo
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Read More

Today's Range

Now: $15.31
Low: $15.31
High: $15.31

50 Day Range

MA: $15.32
Low: $15.31
High: $15.45

2 Week Range

Now: $15.31
Low: $4.75
High: $16.10

Volume

N/A

Average Volume

1,215,776 shs

Market Capitalization

$766.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28